ClinicalTrials.gg
RecruitingNCT07625332Updated Nov 4, 2026

Pilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI)

A Phase 2/3 interventional study of Galantamine Hydrobromide Extended Release in Spinal Cord Injury, Traumatic Spinal Cord Injury and Paraplegia and Tetraplegia, sponsored by Northwell Health. Recruiting at 3 sites in United States. Open to participants aged 21 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Northwell Health · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 4, 2026Start date movedPrimary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
21 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 968 studies in Spinal Cord Injuries with a site in United States — 249 open to participants now, 308 under way, 7 of them phase 3. Spinal Cord Injuries · United States.

Planned enrollment
159th of 836
60 · median 24
Started
2026
with 67 others
Phase 2/3
24 of 968
4 open now
Primary completion
2027-08
later than 169 of 307 live
Registered
938th of 968
by date

Among the 968 studies in Spinal Cord Injuries with a site in United States, this one is the 159th largest by planned enrollment of the 836 interventional ones that give a count, is one of 68 that started in 2026, is one of 24 in phase 2/3, reaches primary completion later than 169 of the 307 other live ones, and was the 938th registered.

Spinal Cord Injuries

2,032 studies on the registry are indexed under Spinal Cord Injuries; 542 are open to participants now.

Browse Spinal Cord Injuries studies →

Open to participants now

249 of the 968 studies in Spinal Cord Injuries with a site in United States are open now. Recruiting first, the newest first:

243 more — sign in →

All 249 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 374 Spinal Cord Injuries studies recruiting now, 167 (45%) set no upper age limit and 156 (42%) stop at 75 or younger; 40 take children under 18; 52 take healthy volunteers.

This study: 21 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 968 studies in Spinal Cord Injuries with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.

03

Conditions studied

  • Spinal Cord Injury
  • Traumatic Spinal Cord Injury
  • Paraplegia and Tetraplegia
  • Metabolic Syndrome

Keywords

  • spinal cord injury
  • tetraplegia
  • paraplegia
  • metabolic syndrome
04

Who can participate

Ages eligible
21 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 21-75 years (male or female)
  • Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)
  • Wheelchair user for community mobility
  • Injury level of tetraplegia (cervical level) or paraplegia (all levels)
  • SCI-specific obesity indicated by waist circumference ≥94 cm
  • Resting heart rate >45 bpm based on 10 measurements over 10 minutes
  • Without cardiovascular abnormalities as indicated by 12-lead
  • Tolerable bowel routine indicated by a score of \<10 on the International SCI Bowel Function Data Set (ISCI-BDS)
  • Metabolic Syndrome (MetS) defined by the presence of at least three of the following: (1) obesity indicated by SCI-specific waist circumference ≥94 cm, (2) elevated fasting glucose ≥100 mg/dL, (3) dyslipidemia: high triglycerides ≥150 mg/dL or low HDL cholesterol \<40 mg/dL for men and \<50 mg/dL for women, (4) C-reactive protein (CRP) levels >1 mg/dL
  • Able to understand and communicate in English at the level of describing adverse event frequency and severity and completing validated outcome measures
  • Willingness to comply with all study procedures and availability for the duration of the study
  • Provision of signed and dated form

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of neurological injury or condition other than SCI
  • Progressive condition that would be expected to change neurological status
  • Signs and symptoms of cardiovascular disease or cardiac arrhythmias
  • Resting heart rate \<45 bpm
  • Score of 10 or greater on the ISCI-BDS v2.1 indicating moderate to severe neurogenic bowel dysfunction
  • Severe concurrent medical disease, condition, or illness judged to be by the site physician
  • Psychopathology documented in the medical record or history that may conflict with study objectives
  • Pregnancy (participant reported or determined by clinical lab test), women who plan to become pregnant, or women who are nursing during the study
  • Active cancer or currently in treatment for cancer
  • Triglyceride levels ≥400 mg/dL
  • Chronic use of medications with known or probable interactions with galantamine
  • Enrolled in another research study that is likely to interfere with conduct or results of the current study
  • Any other reason the site physician feels that participation is contraindicated
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Galantamine ER

    All participants (tetraplegia and paraplegia cohorts) receive galantamine hydrobromide extended release (ER) capsules. Aim 1 (Day 1): single 8mg dose administered orally in the laboratory with at least 5 hours of monitored observation. Aim 2 (Weeks 1-12): 8mg once daily for Weeks 1-4, with dose escalation to 16mg (two 8mg capsules) once daily for Weeks 5-12 based on tolerability. Taken orally in the morning with a meal. The two cohorts (tetraplegia and paraplegia) are analyzed separately as pre-specified subgroups.

    Drug: Galantamine Hydrobromide Extended Release

Interventions

  • DrugExtended-release Galantamine HydrobromideStudies of Extended-release Galantamine HydrobromideExtended-release Galantamine Hydrobromide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Galantamine hydrobromide extended release (ER) capsules, 8mg, administered orally once daily in the morning with a meal. Aim 1: Single 8mg dose in the laboratory with at least 5 hours of observation. Aim 2: 8mg once daily for Weeks 1-4; dose escalated to 16mg once daily (two 8mg capsules) for Weeks 5-12 based on tolerability. If the 16mg dose is not tolerated, the participant returns to 8mg daily. Total treatment duration: 12 weeks.

    Also known as: Razadyne ER

06

What researchers measure

Primary outcomes

  1. Change in ISCI-BDS Neurogenic Bowel Symptoms Score (Aim 1 and Aim 2)

    Neurogenic bowel symptoms assessed using the International SCI Bowel Function Data Set (ISCI-BDS). Worsening will be defined as a negative change in ISCI-BDS score category (e.g., mild to moderate).

    Time frame: Visit 0 (Screening) through Visit 5 (Week 12)

  2. Change in Heart Rate (Avg) During In-Lab Observation (Aim 1)

    Heart rate (beats per minute) measured before administration of galantamine 8mgER and at 15-minute intervals during the in-lab observation period.

    Time frame: Visit 1 (Day 1; pre-dose through 5 hours post-dose)

  3. Change in Blood Pressure During In-Lab Observation (Aim 1)

    Blood pressure (mmHg) measured in the seated position before administration of galantamine 8mgER and at 15-minute intervals during the in-lab observation period.

    Time frame: Visit 1 (Day 1; pre-dose through 5 hours post-dose)

  4. Occurrence of Adverse Events During In-Lab Observation (Aim 1)

    Frequency and severity of all adverse events (AEs) during the in-lab observation period after a single dose of galantamine 8mgER, assessed by standardized AE survey and open-ended questions. AEs are graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The number of participants experiencing at least one AE will be reported.

    Time frame: Visit 1 (Day 1; pre-dose through 5 hours post-dose)

  5. Change in Heart Rate (Avg) During Outpatient Treatment (Aim 2)

    Heart rate (beats per minute) measured at each study visit and daily at home.

    Time frame: Visit 2 (Day 2) through Visit 5 (Week 12)

  6. Change in Blood Pressure During Outpatient Treatment (Aim 2)

    Blood pressure (mmHg) will be measured at each study visit and daily at home

    Time frame: Visit 2 (Day 2) through Visit 5 (Week 12)

  7. Occurrence of Adverse Events During Outpatient Treatment (Aim 2)

    Frequency and severity of all adverse events (AEs) during the 12-week outpatient dose escalation period, assessed at each study visit and via weekly phone calls. AEs are graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 by severity and relationship to study drug. The number of participants experiencing at least one AE will be reported.

    Time frame: Visit 2 (Day 2) through Visit 5 (Week 12)

Secondary outcomes

  1. Change in Inflammatory Cytokines During Outpatient Treatment (Aim 2)

    Inflammatory markers such as: TNF-α, IL-1ß, IL-6, IL-10, and other cytokines (pg/ml) will be measured in plasma at Visit 2 (Day 2) and Visit 5 (Week 12)

    Time frame: Visit 2 (Day 2) and Visit 5 (Week 12)

  2. Change in Plasma Leptin During Outpatient Treatment (Aim 2)

    Plasma leptin levels measured (pg/ml) at Visit 2 (Day 2) and Visit 5 (Week 12)

    Time frame: Visit 2 (Day 2) and Visit 5 (Week 12)

  3. Change in Plasma Adiponectin During Outpatient Treatment (Aim 2)

    Plasma adiponectin levels (µg/mL) measured at Visit 2 (Day 2) and Visit 5 (Week 12)

    Time frame: Visit 2 (Day 2) and Visit 5 (Week 12)

  4. Change in Lipids (HDL, LDL, and Triglycerides)

    High-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (mg/dL) will be measured at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  5. Change in Fasting Plasma Insulin

    Fasting plasma insulin levels (µIU/mL) measured at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  6. Change in Fasting Blood Glucose

    Fasting blood glucose levels (mg/dL) measured at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  7. Change in HOMA-IR From Screening (Aim 2)

    Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) calculated from fasting glucose and fasting insulin (Unitless index ) at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  8. Change in HbA1c From Screening

    Hemoglobin A1c (HbA1c) levels (%) measured at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  9. Change in C-Reactive Protein (CRP)

    C-reactive protein (CRP) levels (mg/L ) measured at Visit 0 (Screening) and Visit 5 (Week 12)

    Time frame: Visit 0 (Screening) and Visit 5 (Week 12)

  10. Change in Body Composition by DXA During Outpatient Treatment (Aim 2)

    Total body fat mass (kg) and total body fat percentage measured by dual-energy X-ray absorptiometry (DXA) total body scan at Visit 2 (Day 2) and Visit 5 (Week 12)

    Time frame: Visit 2 (Day 2) and Visit 5 (Week 12)

  11. Change in Waist and Hip Circumference During Outpatient Treatment (Aim 2)

    Waist and Hip circumference (cm) measured by tape measure at Day 2 and at Week 12.

    Time frame: Visit 2 (Day 2) and Visit 5 (Week 12)

  12. Change in High Frequency Heart Rate Variability (HF-HRV) During Outpatient Treatment (Aim 2)

    High frequency component of heart rate variability (HF-HRV), a valid estimate of cardio-vagal tone (ms²) measured during supine and seated observations Visit 2 (Day 2), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)

    Time frame: Visit 2 (Day 2), Visit 3 (Week 4), Visit 4 (Week 8), and Visit 5 (Week 12)

07

Study locations

2 of 3 sites recruiting
  • Kessler Institute for Rehabilitation
    West Orange, New Jersey 07052, United States
    Not yet recruiting
    • Trevor Dyson-Hudson, MD · Contacttdysonhudson@kesslerfoundation.org · 917-838-3143
    • Matthew Maher, MS · ContactMatthew.Maher@va.gov · 718-584-9000
    • James Wilson, DO · Sub investigator
    • Chris Cirnigliaro, PhD · Sub investigator
    • Trevor Dyson-Hudson, MD · Principal investigator
  • Northwell Health
    Manhasset, New York 11030, United States
    Recruiting
    • Welmi Pello, MPH, RN · Contactwpello@northwell.edu · 516-562-1331
    • Joy Cambe, MD, MPH · Contactjcambe@northwell.edu · 516-562-1331
    • Ona Bloom, PhD · Principal investigator
    • Adam B Stein, MD · Sub investigator
  • James J. Peters VA Medical Center
    The Bronx, New York 10468, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — All data must be de-identified in accordance with institutional, local, state, and federal guidelines.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Oct 2026 (actual). Primary completion is estimated for Aug 2027, 10 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Jun 2026 → Oct 2026 and primary completion Jun 2027 → Aug 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
Jun 4, 2026
StartActual
Oct 15, 2026was Jun 2026
Primary completionEst.
Aug 2027was Jun 2027
CompletionEst.
Dec 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 15, 2026→Oct 15, 2026 (actual)
Nov 4, 2026
Primary completion
Jun 2027→Aug 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Jun 15, 2026→Oct 15, 2026 (now actual)
    Primary completion Jun 2027→Aug 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07625332
Lead sponsor
Northwell Health
Collaborators
Bronx Veterans Medical Research Foundation, Inc, Kessler Institute for Rehabilitation
Responsible party
Sponsor
First posted
Jun 4, 2026
Start date
Oct 15, 2026
Primary completion
Aug 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Ona Bloom, PhD
Contact
obloom@northwell.edu
516-562-1309

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Extended-release Galantamine Hydrobromide

Start the discussion